drugset / Trial / NCT07759895
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
Phase 2
Recruiting
80 enrolled
Amit Lotan
Hadassah Medical Organization · collabHebrew University of Jerusalem · collabJerusalem Mental Health Center · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In following guidelines for studying negative symptoms in schizophrenia, 60 patients aged 18-40, diagnosed with schizophrenia or schizoaffective disorder during the last ten years, will receive a combination of the iron chelator DFP plus NAC or a matching placebo plus NAC combination, as add-on to their maintenance antipsychotic drug (APD) treatment, for a duration of 36 weeks. Prior to initiation of treatment, all participants will undergo baseline MRI scan. A follow-up MRI will be conducted at the end of the 36-week study period, or upon early withdrawal if applicable, to evaluate the effect of the add-on treatment on iron dyshomeostasis and morphology.
Timeline
- Start
- 2026-08-12
- Primary completion
- 2028-12
- Completion
- 2029-12
Publications
- Background Beebe LH, Smith K. Informed consent to research in persons with schizophrenia spectrum disorders. Nurs Ethics. 2010 Jul;17(4):425-34. doi: 10.1177/0969733010364581.
- Background Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol. 2005 Mar 17;5(1):5. doi: 10.1186/1471-2377-5-5.
- Background Blanchet PJ, Rompre PH. Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia. J Clin Psychopharmacol. 2014 Feb;34(1):36-9. doi: 10.1097/JCP.0b013e3182a6a2e3.
- Background Keefe RS, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins K. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res. 2008 Jul;102(1-3):108-15. doi: 10.1016/j.schres.2008.03.024. Epub 2008 May 20.
- Background Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004 Jun 1;68(2-3):283-97. doi: 10.1016/j.schres.2003.09.011.
- Background Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005 Nov 15;79(2-3):231-8. doi: 10.1016/j.schres.2005.04.008. Epub 2005 Jun 27.
- Background Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, Visco AC, Metzler E, Zhang Y, Francis MM. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 2018 Sep;199:395-402. doi: 10.1016/j.schres.2018.03.012. Epub 2018 Mar 24.
- Background Betts MJ, Kirilina E, Otaduy MCG, Ivanov D, Acosta-Cabronero J, Callaghan MF, Lambert C, Cardenas-Blanco A, Pine K, Passamonti L, Loane C, Keuken MC, Trujillo P, Lusebrink F, Mattern H, Liu KY, Priovoulos N, Fliessbach K, Dahl MJ, Maass A, Madelung CF, Meder D, Ehrenberg AJ, Speck O, Weiskopf N, Dolan R, Inglis B, Tosun D, Morawski M, Zucca FA, Siebner HR, Mather M, Uludag K, Heinsen H, Poser BA, Howard R, Zecca L, Rowe JB, Grinberg LT, Jacobs HIL, Duzel E, Hammerer D. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain. 2019 Sep 1;142(9):2558-2571. doi: 10.1093/brain/awz193.
- Background Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006 Jul 1;31(3):968-80. doi: 10.1016/j.neuroimage.2006.01.021. Epub 2006 Mar 10.
- Background Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, Chiang MC, Christensen GE, Collins DL, Gee J, Hellier P, Song JH, Jenkinson M, Lepage C, Rueckert D, Thompson P, Vercauteren T, Woods RP, Mann JJ, Parsey RV. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage. 2009 Jul 1;46(3):786-802. doi: 10.1016/j.neuroimage.2008.12.037. Epub 2009 Jan 13.
- Background Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y, Sakai A. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport. 2006 Jul 31;17(11):1215-8. doi: 10.1097/01.wnr.0000227984.84927.a7.
- Background Shibata E, Sasaki M, Tohyama K, Kanbara Y, Otsuka K, Ehara S, Sakai A. Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla. Magn Reson Med Sci. 2006 Dec;5(4):197-200. doi: 10.2463/mrms.5.197.
- Background Mullins PG, McGonigle DJ, O'Gorman RL, Puts NA, Vidyasagar R, Evans CJ; Cardiff Symposium on MRS of GABA; Edden RA. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage. 2014 Feb 1;86:43-52. doi: 10.1016/j.neuroimage.2012.12.004. Epub 2012 Dec 13.
- Background Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002 Jan 31;33(3):341-55. doi: 10.1016/s0896-6273(02)00569-x.
- Background Stikov N, Campbell JS, Stroh T, Lavelee M, Frey S, Novek J, Nuara S, Ho MK, Bedell BJ, Dougherty RF, Leppert IR, Boudreau M, Narayanan S, Duval T, Cohen-Adad J, Picard PA, Gasecka A, Cote D, Pike GB. In vivo histology of the myelin g-ratio with magnetic resonance imaging. Neuroimage. 2015 Sep;118:397-405. doi: 10.1016/j.neuroimage.2015.05.023. Epub 2015 May 21.
- Background Berman S, Filo S, Mezer AA. Modeling conduction delays in the corpus callosum using MRI-measured g-ratio. Neuroimage. 2019 Jul 15;195:128-139. doi: 10.1016/j.neuroimage.2019.03.025. Epub 2019 Mar 22.
- Background Zhang H, Zhang GF, He ZY, Li ZY, Zhu M, Zhang GX. Evaluation of primary adnexal masses by 3T MRI: categorization with conventional MR imaging and diffusion-weighted imaging. J Ovarian Res. 2012 Nov 14;5(1):33. doi: 10.1186/1757-2215-5-33.
- Background Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys J. 1994 Jan;66(1):259-67. doi: 10.1016/S0006-3495(94)80775-1.
- Background Pasternak O, Sochen N, Gur Y, Intrator N, Assaf Y. Free water elimination and mapping from diffusion MRI. Magn Reson Med. 2009 Sep;62(3):717-30. doi: 10.1002/mrm.22055.
- Background Filo S, Shtangel O, Salamon N, Kol A, Weisinger B, Shifman S, Mezer AA. Disentangling molecular alterations from water-content changes in the aging human brain using quantitative MRI. Nat Commun. 2019 Jul 30;10(1):3403. doi: 10.1038/s41467-019-11319-1.
- Background Lee H, Wiggermann V, Rauscher A, Kames C, Beg MF, Popuri K, Tam R, Lam K, Jacova C, Shahinfard E, Sossi V, Pettersen JA, Hsiung GR. Brain Imaging Abnormalities in Mixed Alzheimer's and Subcortical Vascular Dementia. Can J Neurol Sci. 2023 Jul;50(4):515-528. doi: 10.1017/cjn.2022.65. Epub 2022 May 26.
- Background Shin HG, Lee J, Yun YH, Yoo SH, Jang J, Oh SH, Nam Y, Jung S, Kim S, Fukunaga M, Kim W, Choi HJ, Lee J. chi-separation: Magnetic susceptibility source separation toward iron and myelin mapping in the brain. Neuroimage. 2021 Oct 15;240:118371. doi: 10.1016/j.neuroimage.2021.118371. Epub 2021 Jul 6.
- Background Ben-Eliezer N, Sodickson DK, Block KT. Rapid and accurate T2 mapping from multi-spin-echo data using Bloch-simulation-based reconstruction. Magn Reson Med. 2015 Feb;73(2):809-17. doi: 10.1002/mrm.25156. Epub 2014 Mar 19.
- Background Wang Y, Liu T. Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker. Magn Reson Med. 2015 Jan;73(1):82-101. doi: 10.1002/mrm.25358. Epub 2014 Jul 17.
- Background Yao B, Li TQ, Gelderen Pv, Shmueli K, de Zwart JA, Duyn JH. Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. Neuroimage. 2009 Feb 15;44(4):1259-66. doi: 10.1016/j.neuroimage.2008.10.029. Epub 2008 Nov 5.
- Background Weiskopf N, Suckling J, Williams G, Correia MM, Inkster B, Tait R, Ooi C, Bullmore ET, Lutti A. Quantitative multi-parameter mapping of R1, PD(*), MT, and R2(*) at 3T: a multi-center validation. Front Neurosci. 2013 Jun 10;7:95. doi: 10.3389/fnins.2013.00095. eCollection 2013.
- Background Lutti A, Dick F, Sereno MI, Weiskopf N. Using high-resolution quantitative mapping of R1 as an index of cortical myelination. Neuroimage. 2014 Jun;93 Pt 2:176-88. doi: 10.1016/j.neuroimage.2013.06.005. Epub 2013 Jun 10.
- Background Mezer A, Yeatman JD, Stikov N, Kay KN, Cho NJ, Dougherty RF, Perry ML, Parvizi J, Hua le H, Butts-Pauly K, Wandell BA. Quantifying the local tissue volume and composition in individual brains with magnetic resonance imaging. Nat Med. 2013 Dec;19(12):1667-72. doi: 10.1038/nm.3390. Epub 2013 Nov 3.
- Background Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 May;154:672-6. doi: 10.1192/bjp.154.5.672.
- Background Barnes TR. The Barnes Akathisia Rating Scale--revisited. J Psychopharmacol. 2003 Dec;17(4):365-70. doi: 10.1177/0269881103174013.
- Background Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-9. doi: 10.1111/j.1600-0447.1970.tb02066.x. No abstract available.
- Background Hawley C, Fineberg N, Roberts A, Baldwin D, Sahadevan A, Sharman V. The use of the Simpson Angus Scale for the assessment of movement disorder: A training guide. Int J Psychiatry Clin Pract. 2003;7(4):349-2257. doi: 10.1080/13651500310002986.
- Background Dollfus S, Mach C, Morello R. Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms. Schizophr Bull. 2016 May;42(3):571-8. doi: 10.1093/schbul/sbv161. Epub 2015 Nov 12.
- Background Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008 Nov 30;161(2):213-24. doi: 10.1016/j.psychres.2007.11.012. Epub 2008 Oct 11.
- Background Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB; SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;(416):16-23. doi: 10.1034/j.1600-0447.107.s416.5.x.
- Background Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993 Dec;(22):39-44.
- Background Wongjaikam S, Kumfu S, Khamseekaew J, Chattipakorn SC, Chattipakorn N. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine. Sci Rep. 2017 Mar 13;7:44460. doi: 10.1038/srep44460.
- Background Sumneang N, Kumfu S, Khamseekaew J, Siri-Angkul N, Fucharoen S, Chattipakorn SC, Chattipakorn N. Combined iron chelator with N-acetylcysteine exerts the greatest effect on improving cardiac calcium homeostasis in iron-overloaded thalassemic mice. Toxicology. 2019 Nov 1;427:152289. doi: 10.1016/j.tox.2019.152289. Epub 2019 Sep 19.
- Background Neill E, Rossell SL, Yolland C, Meyer D, Galletly C, Harris A, Siskind D, Berk M, Bozaoglu K, Dark F, Dean OM, Francis PS, Liu D, Phillipou A, Sarris J, Castle DJ. N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms. Schizophr Bull. 2022 Nov 18;48(6):1263-1272. doi: 10.1093/schbul/sbac065.
- Background Dean OM, Mancuso SG, Bush AI, Copolov D, Do KQ, Cuenod M, Conus P, Rossell SL, Castle DJ, Berk M. Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Psychiatry Res. 2015 Dec 30;230(3):982-3. doi: 10.1016/j.psychres.2015.10.037. Epub 2015 Nov 2. No abstract available.
- Background Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008 Sep 1;64(5):361-8. doi: 10.1016/j.biopsych.2008.03.004. Epub 2008 Apr 23.
- Background Yolland CO, Hanratty D, Neill E, Rossell SL, Berk M, Dean OM, Castle DJ, Tan EJ, Phillipou A, Harris AW, Barreiros AR, Hansen A, Siskind D. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust N Z J Psychiatry. 2020 May;54(5):453-466. doi: 10.1177/0004867419893439. Epub 2019 Dec 11.
- Background Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Ruzicka E, Dusek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garcon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Trial of Deferiprone in Parkinson's Disease. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254.
- Background Filo S, Shaharabani R, Bar Hanin D, Adam M, Ben-David E, Schoffman H, Margalit N, Habib N, Shahar T, Mezer AA. Non-invasive assessment of normal and impaired iron homeostasis in the brain. Nat Commun. 2023 Sep 12;14(1):5467. doi: 10.1038/s41467-023-40999-z.
- Background Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, Petrault M, Gouel F, Jonneaux A, Dutheil M, Lachaud C, Lopes R, Kuchcinski G, Auger F, Kyheng M, Duhamel A, Perez T, Pradat PF, Blasco H, Veyrat-Durebex C, Corcia P, Oeckl P, Otto M, Dupuis L, Garcon G, Defebvre L, Cabantchik ZI, Duce J, Bordet R, Devos D. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Antioxid Redox Signal. 2018 Sep 10;29(8):742-748. doi: 10.1089/ars.2017.7493. Epub 2018 Feb 8.
- Background Catts VS, Weickert CS. Gene expression analysis implicates a death receptor pathway in schizophrenia pathology. PLoS One. 2012;7(4):e35511. doi: 10.1371/journal.pone.0035511. Epub 2012 Apr 24.
- Background Morris G, Berk M, Carvalho AF, Maes M, Walker AJ, Puri BK. Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases. Behav Brain Res. 2018 Apr 2;341:154-175. doi: 10.1016/j.bbr.2017.12.036. Epub 2017 Dec 28.
- Background Zhang Y, Catts VS, Shannon Weickert C. Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia. Aust N Z J Psychiatry. 2018 Jul;52(7):690-698. doi: 10.1177/0004867417728805. Epub 2017 Sep 9.
- Background Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, Simmonite M, Fiesal J, Katshu MZ, Qureshi A, Skelton M, Christodoulou NG, Brookes MJ, Morris PG, Liddle PF. Glutathione and glutamate in schizophrenia: a 7T MRS study. Mol Psychiatry. 2020 Apr;25(4):873-882. doi: 10.1038/s41380-018-0104-7. Epub 2018 Jun 22.
- Background Coughlin JM, Yang K, Marsman A, Pradhan S, Wang M, Ward RE, Bonekamp S, Ambinder EB, Higgs CP, Kim PK, Edwards JA, Varvaris M, Wang H, Posporelis S, Ma S, Tsujimura T, Edden RAE, Pomper MG, Sedlak TW, Fournier M, Schretlen DJ, Cascella NG, Barker PB, Sawa A. A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia. Mol Psychiatry. 2021 Jul;26(7):3502-3511. doi: 10.1038/s41380-020-00901-5. Epub 2020 Oct 19.
- Background Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, Do KQ. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16621-6. doi: 10.1073/pnas.0706778104. Epub 2007 Oct 5.
- Background Romano A, Serviddio G, Calcagnini S, Villani R, Giudetti AM, Cassano T, Gaetani S. Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal. Free Radic Biol Med. 2017 Oct;111:281-293. doi: 10.1016/j.freeradbiomed.2016.12.046. Epub 2017 Jan 4.
- Background Zhang N, Yu X, Song L, Xiao Z, Xie J, Xu H. Ferritin confers protection against iron-mediated neurotoxicity and ferroptosis through iron chelating mechanisms in MPP+-induced MES23.5 dopaminergic cells. Free Radic Biol Med. 2022 Nov 20;193(Pt 2):751-763. doi: 10.1016/j.freeradbiomed.2022.11.018. Epub 2022 Nov 15.
- Background Ravanfar P, Syeda WT, Jayaram M, Rushmore RJ, Moffat B, Lin AP, Lyall AE, Merritt AH, Yaghmaie N, Laskaris L, Luza S, Opazo CM, Liberg B, Chakravarty MM, Devenyi GA, Desmond P, Cropley VL, Makris N, Shenton ME, Bush AI, Velakoulis D, Pantelis C. In Vivo 7-Tesla MRI Investigation of Brain Iron and Its Metabolic Correlates in Chronic Schizophrenia. Schizophrenia (Heidelb). 2022 Oct 26;8(1):86. doi: 10.1038/s41537-022-00293-1.
- Background Lotan A, Luza S, Opazo CM, Ayton S, Lane DJR, Mancuso S, Pereira A, Sundram S, Weickert CS, Bousman C, Pantelis C, Everall IP, Bush AI. Perturbed iron biology in the prefrontal cortex of people with schizophrenia. Mol Psychiatry. 2023 May;28(5):2058-2070. doi: 10.1038/s41380-023-01979-3. Epub 2023 Feb 7.
- Background Kidane TZ, Sauble E, Linder MC. Release of iron from ferritin requires lysosomal activity. Am J Physiol Cell Physiol. 2006 Sep;291(3):C445-55. doi: 10.1152/ajpcell.00505.2005. Epub 2006 Apr 12.
- Background Carlson GC, Lin RE, Chen Y, Brookshire BR, White RS, Lucki I, Siegel SJ, Kim SF. Dexras1 a unique ras-GTPase interacts with NMDA receptor activity and provides a novel dissociation between anxiety, working memory and sensory gating. Neuroscience. 2016 May 13;322:408-15. doi: 10.1016/j.neuroscience.2016.02.063. Epub 2016 Mar 3.
- Background White RS, Bhattacharya AK, Chen Y, Byrd M, McMullen MF, Siegel SJ, Carlson GC, Kim SF. Lysosomal iron modulates NMDA receptor-mediated excitation via small GTPase, Dexras1. Mol Brain. 2016 Apr 14;9:38. doi: 10.1186/s13041-016-0220-8.
- Background Xu H, Liu X, Xia J, Yu T, Qu Y, Jiang H, Xie J. Activation of NMDA receptors mediated iron accumulation via modulating iron transporters in Parkinson's disease. FASEB J. 2018 Jun 13:fj201800060RR. doi: 10.1096/fj.201800060RR. Online ahead of print.
- Background Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE 3rd, Papadopoulos V, Snyder SH. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron. 2006 Aug 17;51(4):431-40. doi: 10.1016/j.neuron.2006.07.011.
- Background Xu H, Jiang H, Xie J. New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases. Front Mol Neurosci. 2017 Mar 16;10:71. doi: 10.3389/fnmol.2017.00071. eCollection 2017.
- Background Murphy CE, Walker AK, Weickert CS. Neuroinflammation in schizophrenia: the role of nuclear factor kappa B. Transl Psychiatry. 2021 Oct 14;11(1):528. doi: 10.1038/s41398-021-01607-0.
- Background Parellada E, Gasso P. Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. Transl Psychiatry. 2021 May 6;11(1):271. doi: 10.1038/s41398-021-01385-9.
- Background Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR, Smirnova LP. Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives. Oxid Med Cell Longev. 2021 Jan 23;2021:8881770. doi: 10.1155/2021/8881770. eCollection 2021.
- Background Kahn RS, Sommer IE. The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry. 2015 Feb;20(1):84-97. doi: 10.1038/mp.2014.66. Epub 2014 Jul 22.
- Background Reddy-Thootkur M, Kraguljac NV, Lahti AC. The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies. Schizophr Res. 2022 Nov;249:74-84. doi: 10.1016/j.schres.2020.02.001. Epub 2020 Feb 24.
- Background Nicoletti F, Orlando R, Di Menna L, Cannella M, Notartomaso S, Mascio G, Iacovelli L, Matrisciano F, Fazio F, Caraci F, Copani A, Battaglia G, Bruno V. Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia. Front Psychiatry. 2019 Feb 14;10:49. doi: 10.3389/fpsyt.2019.00049. eCollection 2019.
- Background Best MW, Grossman M, Oyewumi LK, Bowie CR. Examination of the Positive and Negative Syndrome Scale factor structure and longitudinal relationships with functioning in early psychosis. Early Interv Psychiatry. 2016 Apr;10(2):165-70. doi: 10.1111/eip.12190. Epub 2014 Oct 2.
- Background Ventura J, Subotnik KL, Gitlin MJ, Gretchen-Doorly D, Ered A, Villa KF, Hellemann GS, Nuechterlein KH. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res. 2015 Feb;161(2-3):407-13. doi: 10.1016/j.schres.2014.10.043. Epub 2014 Dec 8.
- Background Diaz-Caneja CM, Pina-Camacho L, Rodriguez-Quiroga A, Fraguas D, Parellada M, Arango C. Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr. 2015 Mar 4;1:14005. doi: 10.1038/npjschz.2014.5. eCollection 2015.
- Background Austin SF, Mors O, Budtz-Jorgensen E, Secher RG, Hjorthoj CR, Bertelsen M, Jeppesen P, Petersen L, Thorup A, Nordentoft M. Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort. Schizophr Res. 2015 Oct;168(1-2):84-91. doi: 10.1016/j.schres.2015.07.021. Epub 2015 Aug 8.
- Background Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005 Mar;162(3):495-506. doi: 10.1176/appi.ajp.162.3.495.
- Background Hanson E, Healey K, Wolf D, Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep. 2010 Dec;12(6):563-71. doi: 10.1007/s11920-010-0148-0.
- Background Vita A, Gaebel W, Mucci A, Sachs G, Erfurth A, Barlati S, Zanca F, Giordano GM, Birkedal Glenthoj L, Nordentoft M, Galderisi S. European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022 Sep 5;65(1):e58. doi: 10.1192/j.eurpsy.2022.2316.
- Background Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar;37(2):300-5. doi: 10.1093/schbul/sbq059. Epub 2010 Jun 17.
- Background Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012 May;137(1-3):246-50. doi: 10.1016/j.schres.2012.01.031. Epub 2012 Feb 21.
- Background Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
- Background Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, Giordano GM, Vandevelde A, Nielsen MO, Glenthoj LB, Sabe M, Pezzella P, Bitter I, Gaebel W. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry. 2021 Feb 18;64(1):e23. doi: 10.1192/j.eurpsy.2021.11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Deferiprone | Small molecule | — | — |
| Comparator | N-acetylcysteine | Small molecule | — | — |